On June 3, Medtronic rose 3.59% in pre-market trading, trading at $76.0/share, with trading volume of $4.7317 million. The rally was driven by the company's fiscal Q4 and full-year earnings release, which revealed the strongest annual revenue growth in the past decade.

Medtronic reported Q4 sales of $9.807 billion, exceeding the analyst consensus estimate of $9.635 billion. However, adjusted EPS came in at $1.50, missing the expected $1.54 and representing a 7.41% year-over-year decline. Despite the earnings miss, the market focused on the top-line beat and robust product cycle momentum. The company issued FY2027 adjusted EPS guidance of $5.90 to $6.00. Concurrently, Medtronic announced strategic investments to expand its Affera cardiac ablation portfolio amid growing physician demand, and filed a 510(K) application to extend its Hugo robotic-assisted surgery system into general surgery and gynecology in the U.S.

Medtronic is one of the world's largest medical technology companies, headquartered in Ireland, providing medical devices, services, and solutions across more than 150 countries.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)